Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Context: Randomized controlled trials evaluating real-time continuous glucose monitoring (RT-CGM) patients with type 1 diabetes (T1D) show improved glycemic control, but limited data are available on real-world use. Objective: To assess impact of RT-CGM in real-world settings on glycemic control, hospital admissions, work absenteeism, and quality of life (QOL). Design: Prospective, observational, multicenter, cohort study. Participants: A total of 515 adults with T1D on continuous subcutaneous insulin infusion (CSII) therapy starting in the Belgian RT-CGM reimbursement program. Intervention: Initiation of RT-CGM reimbursement. Main Outcome Measure: Hemoglobin A1c (HbA1c) evolution from baseline to 12 months. Results: Between September 1, 2014, and December 31, 2016, 515 adults entered the reimbursement system. Over this period, 417 (81%) patients used RT-CGM for at least 12 months. Baseline HbA1c was 7.7 ± 0.9% (61 ± 9.8 mmol/mol) and decreased to 7.4 ± 0.8% (57 ± 8.7 mmol/mol) at 12 months (P < 0.0001). Subjects who started RT-CGM because of insufficient glycemic control showed stronger decrease in HbA1c at 4, 8, and 12 months compared with patients who started because of hypoglycemia or pregnancy. In the year preceding reimbursement, 16% of patients were hospitalized for severe hypoglycemia or ketoacidosis in contrast to 4% (P < 0.0005) the following year, with decrease in admission days from 54 to 18 per 100 patient years (P < 0.0005). In the same period, work absenteeism decreased and QOL improved significantly, with strong decline in fear of hypoglycemia. Conclusion: Sensor-augmented pump therapy in patients with T1D followed in specialized centers improves HbA1c, fear of hypoglycemia, and QOL, whereas work absenteeism and admissions for acute diabetes complications decreased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benefits of CGM in this population include reductions in A1C, fewer severe hypoglycemia events in children and adults, increased TIR, as well as significant reductions in hospitalizations for severe hypoglycemia and DKA.156,162–168”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [165]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SPSS survival manual : a step by step guide to data analysis using SPSS
Pallant, J. (2010) · Cited by 6,888
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“statement (11), our trial reports on time in hypoglycemia, time in range, and glucose variability.”
BackgroundContinuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Assessment of Diabetes-Related Distress
Polonsky, W. H., Anderson, B. J., Lohrer, P. A., Welch, G., Jacobson, A. M., Aponte, J. E., & Schwartz, C. E. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.754 · Cited by 1,497
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Hex, N., Bartlett, C., Wright, D., Taylor, M., & Varley, D. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03698.x · Cited by 819 · cited 1×
“Of interest, we also observed a decline in work absenteeism, which is a less visible (but substantial) financial burden to society (22).”
BackgroundFear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579 · cited 1×
“All questionnaires [SF-36 (12), Problem Areas in Diabetes-short form (13–15), andHypoglycemia Fear Survey (HFS)-Worry (16, 17)] were validated in both Belgian languages (Dutch and French) and presented to patients in their mother tongue (Supplemental Table 2).”
Backgroundthe SWITCH Study Group, Battelino, T., Conget, I., Olsen, B., Schütz-Fuhrmann, I., Hommel, E., Hoogma, R., Schierloh, U., Sulli, N., & Bolinder, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2708-9 · Cited by 494
McGuire, B. E., Morrison, T. G., Hermanns, N., Skovlund, S., Eldrup, E., Gagliardino, J., Kokoszka, A., Matthews, D., Pibernik-Okanović, M., Rodríguez-Saldaña, J., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1559-5 · Cited by 424 · cited 1×
“Additionally, almost half of the patients in the RESCUE trial reported problematic emotional distress (15).”
BackgroundPsychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes
Gonder-Frederick, L. A., Schmidt, K. M., Vajda, K. A., Greear, M. L., Singh, H., Shepard, J. A., & Cox, D. J. (2011) · Diabetes Care · doi:10.2337/dc10-1343 · Cited by 337
Research works printed but not linked: 1
- Ware, 1993, SF-36 Health Survey: Manual and Interpretation Guide
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Dhatariya, K. K., Glaser, N. S., Codner, E., & Umpierrez, G. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0165-1 · Cited by 461
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Charleer, S., De Block, C., Van Huffel, L., Broos, B., Fieuws, S., Nobels, F., Mathieu, C., & Gillard, P. (2020) · Diabetes Care · doi:10.2337/dc19-1610 · Cited by 261
Self-citationvan den Boom, L., Karges, B., Auzanneau, M., Rami-Merhar, B., Lilienthal, E., von Sengbusch, S., Datz, N., Schröder, C., Kapellen, T., Laimer, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0345 · Cited by 191
“The use of insulin pumps (7) and CGM (8) in type 1 diabetes treatment has been fostered by rapid technological evolution (6,9), efficacy as demonstrated by clinical trials and scientific reports (1,2,6,8,10), cost-effectiveness encouraging reimbursement by health care systems (6,10,11), and acceptance by patients in t…”
BackgroundTyndall, V., Stimson, R. H., Zammitt, N. N., Ritchie, S. A., McKnight, J. A., Dover, A. R., & Gibb, F. W. (2019) · Diabetologia · doi:10.1007/s00125-019-4894-1 · Cited by 165
Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners
Ajjan, R., Slattery, D., & Wright, E. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0870-x · Cited by 120
Malahi, A. E., Elsen, M. V., Charleer, S., Dirinck, E. L., Ledeganck, K. J., Keymeulen, B., Crenier, L., Radermecker, R. P., Taes, Y., Vercammen, C., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab688 · Cited by 131
Self-citationJohnson, S. R., Holmes-Walker, D. J., Chee, M., Earnest, A., & Jones, T. W. (2022) · Diabetes Care · doi:10.2337/dc21-1666 · Cited by 86
“tion-based studies are limited (2,15), with very few published outcomes for”
BackgroundEvolution of Diabetes Technology
Dovč, K., & Battelino, T. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.009 · Cited by 132
Di Molfetta, S., Di Gioia, L., Caruso, I., Cignarelli, A., Green, S. C., Natale, P., Strippoli, G. F. M., Sorice, G. P., Perrini, S., Natalicchio, A., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3842 · Cited by 76
Increasing Hospitalizations for DKA: A Need for Prevention Programs
Vellanki, P., & Umpierrez, G. E. (2018) · Diabetes Care · doi:10.2337/dci18-0004 · Cited by 78
Meulemeester, J. D., Charleer, S., Visser, M. M., Block, C. E. M. D., Mathieu, C., & Gillard, P. (2024) · Diabetologia · doi:10.1007/s00125-024-06171-y · Cited by 89
“In this retrospective cross-sectional study, data were gathered from 1067 individuals who participated in RESCUE (Reimbursement Study of Continuous Glucose Monitoring in Belgium) [15] and FUTURE (Flash Glucose Monitoring Study for Diabetes) [16] at the University Hospitals of Leuven.”
Self-citationAdvances in Continuous Glucose Monitoring: Clinical Applications
Kwon, S. Y., & Moon, J. S. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2370 · Cited by 94
“Charleer et al. [16] report a fourfold decrease in severe hypoglycemia-relat-ed hospitalizations.”
Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State
Gosmanov, A. R., Gosmanova, E. O., & Kitabchi, A. E. (2021) · Cited by 94
Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease
Klupa, T., Czupryniak, L., Dzida, G. J., Fichna, P., Jarosz-Chobot, P. A., Gumprecht, J., Myśliwiec, M., Szadkowska, A., Bomba-Opon, D. A., Czajkowski, K., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01431-3 · Cited by 94
Time in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 70
Health Care Disparities in Use of Continuous Glucose Monitoring
Isaacs, D., Bellini, N. J., Biba, U., Cai, A., & Close, K. L. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0268 · Cited by 61
Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations
Bailey, T. S., & Alva, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0236 · Cited by 56
“26 Numerous real-world studies have also shown that use of CGM improves overall glycemic control, 27–34 reduces hypo-glycemia risk, 27,28,33–35 and has been shown to reduced the incidence of diabetes-related events and hospitalizations.”
Deiss, D., Szadkowska, A., Gordon, D., Mallipedhi, A., Schütz-Fuhrmann, I., Aguilera, E., Ringsell, C., Block, C. E. M. D., & Irace, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0397 · Cited by 62
Continuous Glucose Monitoring Use in Older Adults for Optimal Diabetes Management
Munshi, M. N. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0111 · Cited by 63
Prevalence, Cost, and Burden of Diabetic Ketoacidosis
Virdi, N. S., Poon, Y., Abaniel, R. M., & Bergenstal, R. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0149 · Cited by 67
“Although use of CGM has been demonstrated to reduce the incidence of DKA, 69,96,97 management of glucose, alone, may not be enough for many individuals who are at increased risk for developing DKA, particularly those treated with SGLTi medications who suffer from euDKA.”
Monitoring of Pediatric Type 1 Diabetes
Marks, B. E., & Wolfsdorf, J. I. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00128 · Cited by 71
Hypoglycemia: New Definitions and Regulatory Implications
Ratner, R. E. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0113 · Cited by 49
“32 Results in type 2 diabetes are less dramatic, due to the decreased frequency of hypoglycemia.”
Murphy, H. R., Feig, D. S., Sanchez, J. J., de Portu, S., Sale, A., & the CONCEPTT Collaborative Group (2019) · Diabetic Medicine · doi:10.1111/dme.14046 · Cited by 49
Landau, Z., Abiri, S., Gruber, N., Levy-Shraga, Y., Brener, A., Lebenthal, Y., Barash, G., Pinhas-Hamiel, O., & Rachmiel, M. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1218-8 · Cited by 48
Economic burden of diabetes-related hypoglycemia on patients, payors, and employers
Shi, L., Fonseca, V. A., & Childs, B. P. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107916 · Cited by 54
Modern diabetes devices in the school setting: Perspectives from school nurses
March, C. A., Nanni, M., Kazmerski, T. M., Siminerio, L. M., Miller, E. P., & Libman, I. M. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13015 · Cited by 54
Burnside, M. J., Williman, J. A., Davies, H. M., Jefferies, C., Paul, R. G., Wheeler, B. J., Wiltshire, E. J., Anderson, Y. C., & de Bock, M. I. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100644 · Cited by 63
Talbo, M. K., Katz, A., Hill, L., Peters, T. M., Yale, J.-F., & Brazeau, A.-S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102119 · Cited by 42
Role of continuous glucose monitoring in the management of glycogen storage disorders
Herbert, M., Pendyal, S., Rairikar, M., Halaby, C., Benjamin, R. W., & Kishnani, P. S. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0200-5 · Cited by 42
“#3 above and established in literature (Charleer et al 2018; Polonsky and Hessler 2013).”
Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
ALMURASHI, A. M., Rodriguez, E., & Garg, S. K. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00348-3 · Cited by 66
Chow, K. W., Kelly, D. J., Rieff, M. C., Skala, P. A., Kravets, I., Charitou, M. M., Morley, E. J., Gupta, R., & Miller, J. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820985263 · Cited by 40
“Please complete the following statement: “rtCGM use decreased my utilization of PPE by ___:” 5% - 2 (12) 10% - 2 (12) 25% - 4 (24) 50% - 4 (24) 75% - 3 (18) No response - 2 (12) N = 35 7.”
BackgroundChoudhary, P., Bellido, V., Graner, M., Altpeter, B., Cicchetti, A., Durand‐Zaleski, I., & Kristensen, F. B. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01132-9 · Cited by 47
Charleer, S., De Block, C., Nobels, F., Radermecker, R. P., Lowyck, I., Mullens, A., Scarnière, D., Spincemaille, K., Strivay, M., Weber, E., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1531 · Cited by 39
Self-citationLavens, A., Nobels, F. R. E., Block, C. E. M. D., Oriot, P., Verhaegen, A. A., Chao, S., Casteels, K., Mouraux, T., Doggen, K., Mathieu, C., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0003 · Cited by 44
Self-citationJanež, A., Battelino, T., Klupa, T., Kocsis, G., Kuricova, M., Lalic, N. M., Stoian, A. P., Prázný, M., Rahelić, D., Šoupal, J., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01160-5 · Cited by 48
Burckhardt, M.-A., Abraham, M. B., Mountain, J., Coenen, D., Paniora, J., Clapin, H., Jones, T. W., & Davis, E. A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0149 · Cited by 36
Galindo, R. J., Parkin, C. G., Aleppo, G., Carlson, A. L., Kruger, D. F., Levy, C. J., Umpierrez, G. E., & McGill, J. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0107 · Cited by 38
Oliver, N. S., Giménez, M., Calhoun, P. M., Cohen, N., Moscardó, V., Hermanns, N., Freckmann, G., Reddy, M., & Heinemann, L. (2019) · Diabetes Care · doi:10.2337/dc19-0977 · Cited by 39
“Realworld data suggest rtCGM system usage may also reduce work absenteeism and hospital admissions for extremes of glucose (severe hypoglycemia or diabetic ketoacidosis) (11).”
Background100 years on: the impact of the discovery of insulin on clinical outcomes
Buse, J. B., Davies, M. J., Frier, B. M., & Philis‐Tsimikas, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002373 · Cited by 43
“58 So far, the narrative has focused on the positive developments for patients in terms of improving outcomes and reducing the daily burden imposed by treatment requirements (figure 3), but the reality may not be so rosy.”
BackgroundAleppo, G., Hirsch, I. B., Parkin, C. G., McGill, J., Galindo, R., Kruger, D. F., Levy, C. J., Forlenza, G. P., Umpierrez, G. E., Grunberger, G., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0268 · Cited by 34
Johnston, A. R., Poll, J. B., Hays, E., & Jones, C. W. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100068 · Cited by 40
Continuous Glucose Monitoring to Optimize Management of Diabetes in Patients with Advanced CKD
Galindo, R. J., de Boer, I. H., Neumiller, J. J., & Tuttle, K. R. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04510422 · Cited by 36
Vrany, E. A., Hill‐Briggs, F., Ephraim, P. L., Myers, A. K., Garnica, P., & Fitzpatrick, S. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1083145 · Cited by 39
“It is well-established that CGM use improves the health and well-being of many patients with diabetes (11, 15, 16).”
BackgroundTechnological advances shaping diabetes care
Aktürk, H. K., & Garg, S. K. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000467 · Cited by 35
The assessment and management of quality of life of older adults with diabetes mellitus
Kassem, L. S., & Aron, D. C. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1737520 · Cited by 40
“less work absenteeism, and improved sleep [134,135].”
Norman, G. J., Paudel, M. L., Parkin, C. G., Bancroft, T., & Lynch, P. M. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0525 · Cited by 36
“16,18 We report findings from analyses of administrative claims data on the association between rtCGM use in individuals with T2D and diabetes-related health care resource utilization costs.”
Benefits and limitations of continuous glucose monitoring in type 1 diabetes
Stone, J. Y., & Bailey, T. S. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1706482 · Cited by 30
“A real-world observational study in people with type 1 diabetes performed in the context of nationwide reimbursement for CGM in the Netherlands estimated a 345,509 Euro cost reduction in the year following reimbursement [41].”
BackgroundDatye, K. A., Tilden, D. R., Parmar, A. M., Goethals, E. R., & Jaser, S. S. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01389-1 · Cited by 34
Psychosocial Aspects of Diabetes Technology
Polonsky, W. H. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.003 · Cited by 29
Price, C. E., Fanelli, J. E., Aloi, J., Anzola, S. C., Vishneski, S. R., Saha, A. K., Woody, C., & Segal, S. (2023) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2023.111090 · Cited by 32
Ridder, F. D., den Brinker, M., & Block, C. E. M. D. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819871903 · Cited by 32
Type 1 diabetes-related distress: Current implications in care
Rodríguez-Muñoz, A., César, M. J. P., Tinahones, F. J., & Martínez‐Montoro, J. I. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.03.030 · Cited by 35
Christensen, M. O., Berg, A. K., Rytter, K., Hommel, E., Thyssen, J. P., Svensson, J., & Nørgaard, K. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0007 · Cited by 28
“3,19,20,22,30 This supports our findings that skin problems because of CSII can increase patients’ PAID scores, although prospective studies are needed to determine the direction of causality.”
Lameijer, A., Lommerde, N., Dunn, T. C., Fokkert, M. J., Edens, M. A., Kao, K., Xu, Y., Gans, R. O. B., Bilo, H. J. G., & van Dijk, P. R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108897 · Cited by 27
Reliability of Inpatient CGM: Comparison to Standard of Care
Price, C. E., Ditton, G., Russell, G. B., & Aloi, J. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211062168 · Cited by 30
“5 35 / 65 Admission diagnosis, n (%) DKA 16 (100) 0 (0) Hypovolemic shock 9 (56) 0 (0) Septic shock 1 (7) 0 (0) Vasopressors utilized 0 (0) 0 (0) Burn 0 (0) 3 (15) Cancer 0 (0) 2 (10) Cardiovascular 0 (0) 4 (20) Gastrointestinal 0 (0) 2 (10) Infectious 0 (0) 5 (25) Orthopedic 0 (0) 3 (15) Pulmonary 0 (0) 1 (5)”
Gavin, J. R., & Bailey, C. J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0211 · Cited by 29
“14 The use of these devices also showed favorable results in improving A1C, reducing hypoglycemia events and hospitalizations, and decreasing days absent from work.”
Utilizing continuous glucose monitoring in primary care practice: What the numbers mean
Edelman, S. V., Cavaiola, T. S., BOEDER, S. C., & Pettus, J. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.10.013 · Cited by 27
Gill, M., Zhu, C., Shah, M., & Chhabra, H. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818777265 · Cited by 27
“More recently, a multicenter, prospective, observational cohort study found that patients with T1DM using an insulin pump and rtCGM experienced fewer hospital admissions for acute diabetes complications, compared to similar patients using an insulin pump without rtCGM.(25) Finally, Parkin et al used health plan admini…”
MethodClosed-loop insulin delivery: current status of diabetes technologies and future prospects
Majeed, W., & Thabit, H. (2018) · Expert Review of Medical Devices · doi:10.1080/17434440.2018.1503530 · Cited by 27
“It differs from conventional SAP, LGS, and PLGS by the use of a control algorithm which automatically modulates insulin delivery both above and below preset insulin infusion rates, to maintain glycaemic levels within the target range [9].”
BackgroundInfluentialXia, J., Hu, S., Xu, J., Hao, H., Yin, C., & Xu, D. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0220 · Cited by 22
Ehrmann, D., Priesterroth, L., SCHMITT, A. J., Kulzer, B., & Hermanns, N. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0096 · Cited by 24
Wright, E. E., Roberts, G. J., Chuang, J. S., Nabutovsky, Y., Virdi, N., & Miller, E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0015 · Cited by 22
Ridder, F. D., den Brinker, M., & Block, C. E. M. D. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819865399 · Cited by 23
Time above range for predicting the development of type 2 diabetes
Marco, A., Pazos-Couselo, M., Moreno-Fernández, J., Díez‐Fernández, A., Alonso‐Sampedro, M., Fernández‐Merino, C., González‐Quintela, A., & Gudé, F. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1005513 · Cited by 25
Use of continuous glucose monitors in low‐ and middle‐income countries: A scoping review
Bernabé‐Ortiz, A., Carrillo-Larco, R. M., Safary, E., Vetter, B., & Lazo‐Porras, M. (2023) · Diabetic Medicine · doi:10.1111/dme.15089 · Cited by 21
The use of technology in type 2 diabetes and prediabetes: a narrative review
Liarakos, A. L., Lim, J. Z. M., Leelarathna, L., & Wilmot, E. G. (2024) · Diabetologia · doi:10.1007/s00125-024-06203-7 · Cited by 27
Integrating Continuous Glucose Monitoring Into Clinical Practices and Patients' Lives
Hirsch, I. B., & Miller, E. M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0233 · Cited by 24
“22 These benefits include reductions in hemoglobin HbA1c, 7,9,11,17,18,23–27 fewer severe hypoglycemia events, 24,25,28 increased time within target glucose range (time in range [TIR]), 11,18,19,29 and reductions in time below range.”
Bratke, H., Margeirsdottir, H. D., Assmus, J., Njølstad, P. R., & Skrivarhaug, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01127-6 · Cited by 20
“trial [13] and in adults in an observational study [14].”
BackgroundEeg‐Olofsson, K., Nathanson, D., Spelman, T. D., Kyhlstedt, M., Bülow, E., Levrat‐Guillen, F., & Bolinder, J. (2024) · Diabetes Care · doi:10.2337/dc24-0690 · Cited by 25
Massa, G., Gys, I., Bevilacqua, E., Wijnands, A., & Zeevaert, R. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.015 · Cited by 24
Evolving Use of Continuous Glucose Monitoring Beyond Intensive Insulin Treatment
Wright, E. E., & Subramanian, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0191 · Cited by 20
“6,7,96 65 Moreover, behavioral interventions that included use of CGM has been shown to improve dietary habits, 51,58,80,82 increase physical activity, 51,54 reduce bodyweight and cardiometabolic risk, 82 and enhance problem-solving skills.”
Murata, T., Kuroda, A., Matsuhisa, M., Toyoda, M., Kimura, M., Hirota, Y., Kato, K., Sawaki, H., Tone, A., Kawashima, S., et al. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820939204 · Cited by 19
Kłak, A., Mańczak, M., Owoc, J., & Olszewski, R. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16047 · Cited by 41
“Various methodologies were the reason for excluding 3 studies with considerable samples [31-33] as they had no control groups.”
BackgroundMethodPietrantonio, F., Vinci, A., Rosiello, F., Alessi, E., Pascucci, M., Rainone, M., Castelli, M. D., Ciamei, A., Montagnese, F., D’Amico, R., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910328 · Cited by 17
“, and acute and long-term complications [4,5].”
Gavin, J. R., & Bailey, C. J. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0057 · Cited by 18
Kusinski, L. C., Brown, J., Hughes, D. J., & Meek, C. L. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292094 · Cited by 21
Sebastián‐Valles, F., Alfonso, J. M., Martín, J. A. A., Jiménez‐Díaz, J., Alday, I. H., Navas-Moreno, V., Joya, T. A., García, M. D. M. F., Gómez, G. L. R., Lobariñas, L. E. L., et al. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02204-x · Cited by 19
“In addition, HbA1c does not allow an appropriate assessment of glycemic variability, time spent in hypoglycemia or within the glucose range, which are becoming increasingly important in clinical practice [8, 9] .”
BackgroundContinuous Glucose Monitoring as a Matter of Justice
Kraaijeveld, S. R. (2020) · HEC Forum · doi:10.1007/s10730-020-09413-9 · Cited by 19
Galindo, R. J., Aleppo, G., Parkin, C. G., Baidal, D. A., Carlson, A. L., Cengiz, E., Forlenza, G. P., Kruger, D. F., Levy, C. J., McGill, J. B., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221144052 · Cited by 19
“18,32,33,39 2.”
Minimising hypoglycaemia in the real world: the challenge of insulin
Mathieu, C. (2021) · Diabetologia · doi:10.1007/s00125-020-05354-7 · Cited by 16
“titrate insulin, as the systems reduce the fear of hypoglycaemia in the majority of users [33].”
BackgroundSelf-citationMiller, E. M., & Miller, K. (2024) · Clinical Diabetes · doi:10.2337/cd23-0077 · Cited by 18
Préau, Y., Galie, S., Schaepelynck, P., Armand, M., & Raccah, D. (2021) · Sensors · doi:10.3390/s21186131 · Cited by 20
Type 1 Diabetes Care in Mexico: An Analysis of the RENACED-DT1 National Registry
Faradji, R. N., Valenzuela-Lara, M., Menchaca, A. P. D.-B., Almeda‐Valdés, P., Antonio‐Villa, N. E., Vidrio-Velázquez, M., Islas-Ortega, L., Ramos-Méndez, A. M., la Garza-Hernández, N. E. D., Bustamante-Martínez, J. F., et al. (2021) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.20000498 · Cited by 26
How use of continuous glucose monitoring can address therapeutic inertia in primary care
Martens, T. W., & Parkin, C. G. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2080419 · Cited by 16
“try and database studies have demonstrated a strong link between CGM use and reductions in hospitalizations for diabetic ketoacidosis (DKA) and severe hypoglycemia [43,44,48,58,59].”
BackgroundCharleer, S., Gillard, P., Vandoorne, E., Cammaerts, K., Mathieu, C., & Casteels, K. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13128 · Cited by 14
Self-citationContinuous Glucose Monitoring in Pediatric Diabetic Ketoacidosis
Pott, T., Jimenez‐Vega, J., Parker, J., & Fitzgerald, R. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221140430 · Cited by 14
Billion, L., Charleer, S., Verbraeken, L., Sterckx, M., Vangelabbeek, K., Block, N. D., Janssen, C., Dessel, K. V., Dirinck, E. L., PEIFFER, F. W., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14527 · Cited by 15
Self-citationRole of Continuous Glucose Monitoring in Insulin-Requiring Patients with Diabetes
Welsh, J. B. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0100 · Cited by 17
Scharf, J., Nguyen, X. Q., Vu-Eickmann, P., Krichbaum, M., & Loerbroks, A. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818789143 · Cited by 14
Stimson, R. H., Dover, A. R., Ritchie, S. A., Wright, R. J., McKnight, J. A., Zammitt, N. N., & Gibb, F. W. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001292 · Cited by 14
Messer, L. H., Cook, P. F., Lowe, N. K., Hood, K. K., Driscoll, K. A., & Hernandez, T. L. (2021) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2021.11.016 · Cited by 15
CASTORINO, K. N., Durnwald, C. P., Ehrenberg, S., Ehrhardt, N. M., Isaacs, D., Levy, C. J., Valent, A. M., & Continuous Glucose Monitoring for Gestational Diabetes Management Working Group (2024) · Journal of Women s Health · doi:10.1089/jwh.2023.0864 · Cited by 15
Perera, R., Oliver, N. S., Wilmot, E. G., & Marriott, C. (2018) · Diabetic Medicine · doi:10.1111/dme.13766 · Cited by 12
Wang, Y., Zou, C., Na, H., Zeng, W., & Li, X. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/2851572 · Cited by 12
“Continuous glucose monitoring (CGM) is a dynamic glucose monitoring method that includes an inserting subcutaneous sensor, which can automatically measure the individual interstitial glucose level all day and understand the patient’s blood glucose fluctuation by providing an ambulatory glucose profile (AGP) [8].”
MethodRidder, F. D., Braspenning, R., Ordóñez, J., Klarenbeek, G., Lauwers, P., Ledeganck, K. J., Delbeke, D., & Block, C. E. M. D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301041 · Cited by 13
Messer, L. H., Vigers, T., Pyle, L. L., Fivekiller, E. E., Wadwa, R. P., Hernandez, T. L., & Cook, P. F. (2022) · Diabetic Medicine · doi:10.1111/dme.14910 · Cited by 12
“(3) I want to manage my diabetes today.”
BackgroundRidder, F. D., Charleer, S., Jacobs, S., Bolsens, N., Ledeganck, K. J., Aken, S. V., Vanbesien, J., Gies, I., Casteels, K., Massa, G., et al. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.991633 · Cited by 12
Self-citation
Metadata
- Authors
- Charleer, S., Mathieu, C., Nobels, F., De Block, C., Radermecker, R. P., Hermans, M. P., Taes, Y., Vercammen, C., T'Sjoen, G., Crenier, L., Fieuws, S., Keymeulen, B., Gillard, P., & RESCUE Trial Investigators
- Affiliations
- Research Foundation - Flanders (BE)
- KU Leuven (BE)
- Onze Lieve Vrouwziekenhuis Hospital (BE)
- Department of Endocrinology, Diabetology and Metabolism, University of Antwerp–Antwerp University Hospital, Antwerp, Belgium
- Department of Diabetes, Nutrition and Metabolic Disorders, Centre Hospitalier Universitaire Liege–Liege University, Liege, Belgium
- Cliniques Universitaires Saint-Luc (BE)
- AZ Sint-Jan (BE)
- Imelda Hospital (BE)
- Ghent University Hospital (BE)
- Université Libre de Bruxelles (BE)
- Hasselt University (BE)
- Vrije Universiteit Brussel (BE)
- Corresponding author
- Gillard, Pieter
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-01-12
- Volume
- 103
- Issue
- 3
- Pages
- 1224-1232
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791573153
- Cited by
- 196
- References
- 29
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 23 · 2023: 22 · 2022: 27 · 2021: 39 · 2020: 15 · 2019: 22 · 2018: 11
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Lirias (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Fonds Wetenschappelijk Onderzoek (10.13039/501100003130, http://dx.doi.org/10.13039/501100003130, 1S13517N, 501100003130)
- Vlaamse regering
- Horizon 2020 Framework Programme
- Universitaire Ziekenhuizen Leuven, KU Leuven
- H2020 European Institute of Innovation and Technology (http://dx.doi.org/10.13039/100010686)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, type 1 diabetes, glycemic control, HbA1c, hospitalization, absenteeism, quality of life, fear of hypoglycemia, insulin pump therapy, sensor-augmented pump therapy, hypoglycemia, diabetic ketoacidosis
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Hospitalization, Humans, Hypoglycemia, Male, Middle Aged, Prospective Studies, Quality of Life, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.